Home

AARS (human)

Overview AARS Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala- AMP and then transferred to the acceptor end of tRNA(Ala). Also edits incorrectly charged tRNA(Ala) via its editing domain. Defects in AARS are the cause of Charcot-Marie-Tooth disease type 2N (CMT2N). It is an axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies(designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. Nerve conduction velocities are normal or slightly reduced. Belongs to the class-II aminoacyl-tRNA synthetase family. Note: This description may include information from UniProtKB. Protein type: EC 6.1.1.7; Ligase; Translation Cellular Component: cytoplasm; cytosol Molecular Function: amino acid binding; metal ion binding; alanine-tRNA ligase activity; ATP binding; tRNA binding Biological Process: skin development; protein folding; unfolded protein response; tRNA processing; cerebellar Purkinje cell layer development; tRNA modification; response to amino acid stimulus; tRNA aminoacylation for protein translation; hair follicle development; gene expression; negative regulation of neuron apoptosis; neuromuscular process controlling balance; alanyl-tRNA aminoacylation Reference #:  P49588 (UniProtKB) Alt. Names/Synonyms: AARS; alanine tRNA ligase 1, cytoplasmic; Alanine--tRNA ligase; alanyl-tRNA synthetase; Alanyl-tRNA synthetase, cytoplasmic; AlaRS; CMT2N; Renal carcinoma antigen NY-REN-42; SYAC Gene Symbols: AARS Molecular weight: 106,810 Da Basal Isoelectric point: 5.34  Predict pI for various phosphorylation states

Select Structure to View Below AARS

STRING  |  Scansite  |  Phospho.ELM  |  NetworKIN  |  Pfam  |  ENZYME  |  DISEASE  |  Source  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene

	Modification Sites and Domains	Show Modification Legend
Click here to view phosphorylation modifications only

	Modification Sites in Parent Protein, Orthologs, and Isoforms	Show Modification Legend

SS  SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.	MS  MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.			human
0	2		K19-a	QRFIDFFkRNEHTYV
0	1		K19-u	QRFIDFFkRNEHTYV
0	1		T72	KLSRAANTQKCIRAG
0	1		K74	SRAANTQKCIRAGGk
0	2		K81-a	KCIRAGGkHNDLDDV
0	1		K81-u	KCIRAGGkHNDLDDV
0	3		Y192-p	GPCSEIHyDRIGGRD
0	10		K231-u	READGILkPLPKkSI
0	1		K236-u	ILkPLPKkSIDTGMG
0	1		K282-u	GARPYTGkVGAEDAD
0	2		K338-u	AVRYAHEkLNASRGF
0	1		K366-u	DAFPELKkDPDMVkD
0	3		K366-a	DAFPELKkDPDMVkD
0	1		K372-u	KkDPDMVkDIINEEE
0	11		K384-u	EEEVQFLkTLSRGRR
0	2		K396-u	GRRILDRkIQsLGDS
0	3		S399-p	ILDRkIQsLGDSKTI
0	2		K451-u	ERKLAQLkSQGKGAG
0	1		K486-u	EVTDDSPkYNYHLDS
0	2		K513-u	VMALRREkMFVEEVS
0	3		Y543-p	AEQGGQIyDEGYLVK
0	1		S555-p	LVKVDDSsEDKTEFT
0	15		K564-u	DKTEFTVkNAQVRGG
0	18		K625-u	VLGEADQkGsLVAPD
0	1		S627-p	GEADQkGsLVAPDRL
0	9		K641-u	LRFDFTAkGAMSTQQ
0	3		K650-u	AMSTQQIkkAEEIAN
0	1		K651-u	MSTQQIkkAEEIANE
0	2		K664-u	NEMIEAAkAVyTQDC
0	15		Y667-p	IEAAkAVyTQDCPLA
0	16		K677-u	DCPLAAAkAIQGLRA
0	1		T689-p	LRAVFDEtyPDPVRV
0	5		Y690-p	RAVFDEtyPDPVRVV
0	62		K747-u	VTEEAIAkGIRRIVA
0	19		K762-u	VTGAEAQkALRKAES
0	6		K772-u	RKAESLKkCLSVMEA
0	1		K780-u	CLSVMEAkVKAQTAP
0	1		K789-u	KAQTAPNkDVQREIA
0	2		K812-u	AVIPQWQkDELRETL
0	2		K820-u	DELRETLkSLKKVMD
0	1		K846	KRVLEKTKQFIDSNP
0	2		K876-a	KALNEALkLFKMHSP
0	5		K876-u	KALNEALkLFKMHSP
0	1		K879	NEALkLFKMHSPQTS
0	2		K930-a	VSGLMDGkGGGkDVs
0	1		K930-u	VSGLMDGkGGGkDVs
0	4		K934-u	MDGkGGGkDVsAQAt
0	1		S937-p	kGGGkDVsAQAtGkN
0	1		T941-p	kDVsAQAtGkNVGCL
0	1		K943-u	VsAQAtGkNVGCLQE

	mouse
R19	ERFINFFRRNEHTYV
R19	ERFINFFRRNEHTYV
T72-p	KLSRAANtQkCIRAG
K74-u	SRAANtQkCIRAGGK
K81	kCIRAGGKHNDLDDV
K81	kCIRAGGKHNDLDDV
Y192-p	GPCSEIHyDRIGGRD
K231-u	RESDGVLkPLPKKSI
K236	VLkPLPKKSIDTGMG
K282	GARPYTGKVGAEDAD
K338	AVRYSHEKLNASRGF
K366	DAFPELKKDPEMVKD
K366	DAFPELKKDPEMVKD
K372	KKDPEMVKDIINEEE
K384-u	EEEVQFLkTLSRGRR
K396	GRRILDRKIQsLGDC
S399-p	ILDRKIQsLGDCKTI
K451	ERRLAQLKSQGKGAG
K486	EATDDSPKYNYQSDS
K513	VLALRREKMFVDEVV
Y543	AEQGGQIYDEGYLVK
S555	LVKVDDSSEDKTEFT
K564	DKTEFTVKNAQVRGG
K625-u	VLGEADQkGSLVAPD
S627	GEADQkGSLVAPDRL
K641-u	LRFDFTAkGAMSTQQ
K650	AMSTQQIKKAEEIVN
K651	MSTQQIKKAEEIVNG
K664	NGMIEAAKPVYTQDC
Y667	IEAAKPVYTQDCPLA
K677	DCPLAAAKAIQGLRA
T689	LRAVFDETYPDPVRV
Y690	RAVFDETYPDPVRVV
K747-u	VTEEAIAkGIRRIVA
K762	VTGAEAQKALRKSET
K772	RKSETLKKSLSAMEA
K780	SLSAMEAKVKAQTAP
K789	KAQTAPNKDVQREIA
K812	AVIPQWQKDEQRETL
K820-u	DEQRETLkSLKKVMD
K846-u	KRVLEKTkQLIDSNP
K876	KALNEALKLFkTHSP
K876-u	KALNEALkLFkTHSP
K879-u	NEALkLFkTHSPQTS
K930-a	VSGLMDGkGGGKDMS
K930	VSGLMDGKGGGKDMS
K934	MDGkGGGKDMSAQAT
S937	kGGGKDMSAQATGKN
T941	KDMSAQATGKNVGCL
K943	MSAQATGKNVGCLQE

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E Produced by 3rd Millennium  |  Design by Digizyme ©2003-2013 Cell Signaling Technology, Inc.